Follow
Tobias Meissner
Tobias Meissner
Avera Cancer Institute
Verified email at avera.org
Title
Cited by
Cited by
Year
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
L Rasche, SS Chavan, OW Stephens, PH Patel, R Tytarenko, C Ashby, ...
Nature communications 8 (1), 268, 2017
3452017
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
D Hose, T Rème, T Hielscher, J Moreaux, T Messner, A Seckinger, ...
Haematologica 96 (1), 87, 2011
2242011
Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma
L Rasche, E Angtuaco, JE McDonald, A Buros, C Stein, C Pawlyn, ...
Blood, The Journal of the American Society of Hematology 130 (1), 30-34, 2017
2152017
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
N Weinhold, C Ashby, L Rasche, SS Chavan, C Stein, OW Stephens, ...
Blood, The Journal of the American Society of Hematology 128 (13), 1735-1744, 2016
2132016
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
AC Sprynski, D Hose, L Caillot, T Réme, JD Shaughnessy Jr, B Barlogie, ...
Blood, The Journal of the American Society of Hematology 113 (19), 4614-4626, 2009
2002009
Induction of angiogenesis by normal and malignant plasma cells
D Hose, J Moreaux, T Meissner, A Seckinger, H Goldschmidt, A Benner, ...
Blood, The Journal of the American Society of Hematology 114 (1), 128-143, 2009
1492009
Functional expression of dental plaque microbiota
SN Peterson, T Meissner, AI Su, E Snesrud, AC Ong, NJ Schork, WA Bretz
Frontiers in Cellular and infection microbiology 4, 108, 2014
1172014
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
D Hose, T Rème, T Meissner, J Moreaux, A Seckinger, J Lewis, V Benes, ...
Blood, The Journal of the American Society of Hematology 113 (18), 4331-4340, 2009
1132009
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis
A Seckinger, T Meissner, J Moreaux, H Goldschmidt, GM Fuhler, ...
Oncogene 28 (44), 3866-3879, 2009
912009
Clinical and prognostic role of annexin A2 in multiple myeloma
A Seckinger, T Meiβner, J Moreaux, D Depeweg, J Hillengass, K Hose, ...
Blood, The Journal of the American Society of Hematology 120 (5), 1087-1094, 2012
902012
Omics Pipe: a community-based framework for reproducible multi-omics data analysis
KM Fisch, T Meißner, L Gioia, JC Ducom, TM Carland, S Loguercio, AI Su
Bioinformatics 31 (11), 1724-1728, 2015
892015
Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays
K Mahtouk, J Moreaux, D Hose, T Rème, T Meißner, M Jourdan, JF Rossi, ...
BMC cancer 10, 1-18, 2010
782010
Gene expression profiling in multiple myeloma—reporting of entities, risk, and targets in clinical routine
T Meißner, A Seckinger, T Rème, T Hielscher, T Möhler, K Neben, ...
Clinical Cancer Research 17 (23), 7240-7247, 2011
552011
miRNAs in multiple myeloma–a survival relevant complex regulator of gene expression
A Seckinger, T MeiΔner, J Moreaux, V Benes, J Hillengass, M Castoldi, ...
Oncotarget 6 (36), 39165, 2015
522015
Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6
M Witzens-Harig, D Hose, S Jünger, C Pfirschke, N Khandelwal, ...
Blood, The Journal of the American Society of Hematology 121 (22), 4493-4503, 2013
522013
Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
JS Waizenegger, I Ben-Batalla, N Weinhold, T Meissner, M Wroblewski, ...
Leukemia 29 (3), 696-704, 2015
432015
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression
N Li, DC Johnson, N Weinhold, JB Studd, G Orlando, F Mirabella, ...
Nature communications 7 (1), 13656, 2016
422016
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
V Wagner, D Hose, A Seckinger, L Weiz, T Meißner, T Rème, I Breitkreutz, ...
Oncotarget 5 (21), 10237, 2014
422014
The 7p15. 3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells
N Weinhold, T Meissner, DC Johnson, A Seckinger, J Moreaux, A Försti, ...
Haematologica 100 (3), e110, 2015
332015
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression
M Ali, R Ajore, AK Wihlborg, A Niroula, B Swaminathan, E Johnsson, ...
Nature communications 9 (1), 1649, 2018
312018
The system can't perform the operation now. Try again later.
Articles 1–20